Local volunteers play valuable role in developing new medicines in Croydon

Posted:
21
March 2014

Richmond Pharmacology is proud to announce that its clinical trial volunteers recognise the value of the research they contribute to. The results come from recent internal polling conducted by the organisation.

The poll of 217 local volunteers, drawn from Croydon and surrounding areas, showed that over 90% were happy to continue their relationship with Richmond. Volunteers currently help to develop new medicines for some of the biggest killers, including cancer, lung disease and diabetes.

Among reasons given for their involvement, nearly a quarter of volunteers said that they had benefitted from either learning more about their medical status or enjoying the experience of the study.

Staff members were also singled out for praise. One respondent praised the some 100 local staff that work at Richmond, saying there was great team morale and the patients don't feel strange to be in a hospital and do the clinical trial.

Richmond's globally recognised clinical research facility has been based at Croydon University Hospital since 2005. Over 60% of respondents also felt that having a clinical research organisation like Richmond was beneficial to both the hospital and the local area.

Dr Jorg Taubel, founder and CEO of Richmond Pharmacology said I'm delighted by these results. Healthy volunteers and patients are the heart of what we do and I'm glad that so many want to continue contributing to the development of better and much needed novel medicines.

�We have been working closely with the people of Croydon for eight years and I'm proud that these volunteers recognize our contribution to Croydon's main hospital and the contribution we make towards the regeneration of the local area.�

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more